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Introduction
Transvenous lead extraction is the gold standard for lead
removal. Within recent years the number of lead removal pro-
cedures has constantly increased secondary to the increasing
use of cardiac implantable electronic devices (pacemakers
and implantable cardioverter-defibrillators).1–3 With
increasing prevalence, extraction techniques have greatly
evolved but have also become increasingly challenging in a
progressively elderly patient population with increasingly
complex device systems. The chief indication for lead
removal remains device infection, a class I indication for
complete system extraction.2 Different lead extraction ap-
proaches exist. The standard approach is a stepwise proced-
ure, beginning with simple traction from the venous entry
site, followed by the use of nonpowered traction tools,
so-called locking stylets and mechanical dilator sheaths
(polypropylene or polytetrafluoroethylene) to dissect lead-
to-vessel, lead-to-endocardial, and lead-to-lead adhesions.
A common third step is the use of powered extraction sheaths
that apply some form of energy to forcefully disrupt the
aforementioned adhesions. These tools encompass laser
sheaths (pulsed ultraviolet laser), electrosurgical sheaths (ra-
diofrequency), and, as the newest alternative, “hand-pow-
ered” rotating threaded tip sheaths with rotating sharp
blades at the tip of the sheath.2 The majority of leads can
be extracted successfully through the initial venous entry
site. In some cases, however, usually after long dwell times,
crossover to the right internal jugular vein (Pisa approach) or,
more commonly, the femoral vein allows for a better traction
angle. Thus, detailed anatomical knowledge, including the
awareness of thoracic venous anomalies, is vital for proce-
dural success. We present the rare but classic case of success-
ful mechanical transvenous lead removal in a patient with
persistent left superior vena cava. Our objective is to create
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awareness of thoracic venous anomalies and their implica-
tions for transvenous lead removal, a procedure of increasing
relevance in modern cardiology.
Case report
A 70-year-old man with dilated cardiomyopathy (left ventric-
ular ejection fraction 29%, sinus rhythm 62 beats per minute)
and cardiac resynchronization therapy defibrillator device
implanted 11 years ago (right atrial lead: St. Jude Medical
Tendril SDX 1688Tl; right ventricular lead: St. Jude Med-
ical Riata 1582; bipolar coronary sinus lead: QuickSite
1056T) via a persistent left superior vena cava (PLSVC)
(Figure 1A) was referred to our center for complete device
and lead removal because of lead endocarditis with a 16 !
10 mm mobile vegetation attached to one of the leads
traversing in the right atrium, and Staphylococcus capitis–
positive blood cultures, complicated with a lumbar spondylo-
discitis and a psoas abscess (Figure 1B). Chest radiography
also revealed conductor externalization of the implanted 8F
single-coil Riata defibrillator lead (Figure 1A’), a well-
known problem of this type of defibrillator lead. The right
transjugular (Pisa) approach was initially considered for the
presumably difficult extraction of the long-standing and
externalized Riata lead in the presence of a PLSVC. Phlebog-
raphy performed via the right internal jugular venous access
showed a type II PLSVC anomaly with complete absence of a
right superior vena cava (Figure 1C), thus leaving no reason-
able superior alternative to the standard approach from the
venous entry site. The procedure was carried out under inva-
sive blood pressure monitoring and conscious sedation. The
cardiac resynchronization therapy device pocket was opened,
showing signs of chronic pocket infection. After disconnec-
tion of the generator, the leads were mobilized up to the
venous entry site. The active-fixation mechanism was
released and locking stylets were inserted in all 3 leads.
The right atrial active-fixation lead was extracted effortlessly
using an EZ locking stylet (Spectranetics, Colorado Springs,
CO), inserted all the way to the tip of the lead, and a single
Byrd telescoping polypropylene dilator sheath (Cook Medi-
cal LLC, Bloomington, IN). Mobilization of the left ventric-
ular lead, in which an EZ locking stylet could be advanced
almost completely (0.5 cm proximal of the tip), was more
difficult owing to strong lead-to-vessel interaction, which
was stepwise dissected using several Byrd telescoping poly-
propylene dilator sheaths. Similarly, the right ventricular
Riata defibrillator lead showed extensive lead-to-vessel inter-
action. A Spectranetics 2 locking stylet (Spectranetics,
Figure 1 Transvenous lead extraction in a patient with type II persistent left superior vena cava (PLSVC). A: Chest radiograph showing the cardiac resynch-
ronization therapy defibrillator device, implanted through the PLSVC. Inset (A’): Lateral chest radiograph excerpt with externalization of the Riata lead (arrow).
B: Transesophageal echocardiogram with a large mobile vegetation 10! 16 mm on a lead traversing the right atrium. C: Phlebography from the right jugular
vein, depicting the absence of a right superior vena cava (type II PLSVC).
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Colorado Springs, CO) was inserted all the way to the tip.
During manual adherence dilatation and dissection of the
lead using several Byrd telescoping polypropylene dilator
sheaths, increasing externalization of the high-voltage con-
ductors occurred, which finally necessitated the use a me-
chanical 13F Evolution RL controlled-rotation dilator
sheath (Cook Medical LLC, Bloomington, IN) for successful
lead extraction (Figure 2 and Supplemental Video). After
successful removal of all 3 leads, infected tissue was resected
from the pocket, and, along with the lead tips, was sent for
cultures. A gentamycin-impregnated collagen sponge and re-
don drain were left behind in the pocket before wound
closure.
Thoracic venous anomalies, like the rare type II PLSVC in
our case, may not only make conventional de novo implanta-
tion of pacing and defibrillator leads challenging, but also
hamper nonsurgical transvenous lead extraction from the
venous entry or alternative venous access sites.
Discussion
Although the risk of device implantation has decreased
tremendously over time, significant risk remains associ-
ated with device extraction, a problem of increasing clin-
ical relevance. Recent outcome data from the ELECTRa
registry indicate that overall safety of nonsurgical, transve-
nous lead extraction is good, indicating an in-hospital ma-
jor complication rate of 1.7% and a procedure-related
mortality rate of 0.5%.4 Though rare, complications of
transvenous lead extraction are frequently catastrophic
and require prompt surgical rescue. Operator experience
is a major determinant of safety.5 In rare cases, for
example with thoracic venous anomalies, operator experi-
ence is of even more importance. In this case, leads were
in situ for more than 10 years and strong lead-to-lead and
lead-to-vessel interaction, as well as lead-to–myocardial
tissue (valves, coronary sinus) interaction, were to be ex-
pected. Therefore, surgical and different percutaneous ac-
cess should be carefully considered preoperatively and
perioperatively. The different vascular access sites result
in different traction angles and different traction force vec-
tors for lead-tip removal. In case the extraction via the
initial venous entry site does not result in successful lead
removal, the right jugular approach is often the preferred
access site for removal of a coronary sinus or right ventric-
ular lead, whereas a femoral approach could have been
helpful for right atrial lead removal (Figure 3). Impor-
tantly, lead implantation via a PLSVC does not rule out
the presence of a residual right superior vena cava, which
is the most common form of PLSVC. Therefore, a combi-
nation of several vascular access sites, potentially with the
use of snaring tools, had to be considered during optimal
preparation of the case.
In summary, overall mortality of patients with device
infection, even after complete device removal and adju-
vant antibiotic therapy, ranges as high as 18% at 1 year
and 28% at 3 years.6 Thus, prompt referral of this patient
population to specialized centers with well-trained teams is
essential.2,5
Figure 2 Radiography showing the 13F mechanical dilator sheath during
transvenous extraction of the defibrillator lead.
Figure 3 Possible venous access sites for endovascular lead removal; ar-
rows indicating the additional optimal traction force lines for coronary sinus
(CS) and right ventricular (RV) removal (green) and right atrial (RA)
removal (blue), in case the initial implantation site access (dotted red line)
is not successful.
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Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hrcr.202
0.11.025.
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